![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Acquisition includes, DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.
Lead Product(s): Pluronic Lecithin
Therapeutic Area: Dermatology Product Name: Diffusimax
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Medisca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 28, 2022